Palatin Technologies Stock Price, News & Analysis (NYSEAMERICAN:PTN)

$0.97 -0.01 (-1.02 %)
(As of 02/23/2018 01:55 AM ET)
Previous Close$0.98
Today's Range$0.96 - $0.99
52-Week Range$0.29 - $1.05
Volume899,442 shs
Average Volume1.25 million shs
Market Capitalization$185.55 million
P/E Ratio8.08
Dividend YieldN/A
Beta1.82

About Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies logoPalatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio8.08333333333333
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.12
Net IncomeN/A
Net Margins39.36%
Return on Equity10,489.06%
Return on Assets79.22%

Miscellaneous

EmployeesN/A
Outstanding Shares195,370,000

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Monday, February, 12th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.19. The biopharmaceutical company earned $10.61 million during the quarter. Palatin Technologies had a return on equity of 10,489.06% and a net margin of 39.36%. During the same period last year, the business earned ($0.06) earnings per share. View Palatin Technologies' Earnings History.

Where is Palatin Technologies' stock going? Where will Palatin Technologies' stock price be in 2018?

2 analysts have issued 12-month price targets for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' share price to reach $4.00 in the next year. View Analyst Ratings for Palatin Technologies.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,092,813 shares, an increase of 6.6% from the January 12th total of 6,521,998 shares. Based on an average trading volume of 1,101,308 shares, the days-to-cover ratio is currently 5.5 days. Approximately 3.4% of the company's stock are short sold.

Who are some of Palatin Technologies' key competitors?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the folowing people:

  • John K. A. Prendergast Ph.D., Chairman of the Board (Age 63)
  • Carl Spana Ph.D., President, Chief Executive Officer, Director (Age 53)
  • Stephen T. Wills CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary (Age 59)
  • Anthony M. Manning Ph.D., Director (Age 55)
  • Robert K. deVeer Jr., Independent Director (Age 70)
  • Alan William Dunton M.D., Independent Director (Age 61)
  • Zola P. Horovitz Ph.D., Independent Director (Age 80)
  • Joseph Stanley Hull, Independent Director (Age 64)

Who owns Palatin Technologies stock?

Palatin Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.89%), Deutsche Bank AG (0.70%), Acadian Asset Management LLC (0.66%), Virtu Financial LLC (0.33%), Macquarie Group Ltd. (0.24%) and Millennium Management LLC (0.14%). View Institutional Ownership Trends for Palatin Technologies.

Who bought Palatin Technologies stock? Who is buying Palatin Technologies stock?

Palatin Technologies' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, Acadian Asset Management LLC, Macquarie Group Ltd., Virtu Financial LLC, Millennium Management LLC, Arrowstreet Capital Limited Partnership and Wells Fargo & Company MN. View Insider Buying and Selling for Palatin Technologies.

How do I buy Palatin Technologies stock?

Shares of Palatin Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of Palatin Technologies stock can currently be purchased for approximately $0.97.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $185.55 million.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.


MarketBeat Community Rating for Palatin Technologies (PTN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Palatin Technologies (NYSEAMERICAN:PTN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$2.68
Price Target Upside: 422.74% upside422.74% upside422.74% upside650.58% upside

Palatin Technologies (NYSEAMERICAN:PTN) Consensus Price Target History

Price Target History for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN:PTN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/13/2017Canaccord GenuitySet Price TargetBuy$6.00View Rating Details
10/29/2017Roth CapitalSet Price TargetBuy$2.00View Rating Details
9/22/2016S&P Equity ResearchLower Price Target$0.61 -> $0.55View Rating Details
(Data available from 2/23/2016 forward)

Earnings

Palatin Technologies (NYSEAMERICAN:PTN) Earnings History and Estimates Chart

Earnings by Quarter for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN PTN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018Q2 18($0.18)$0.01$10.61 millionViewListenView Earnings Details
11/13/2017Q1 18$0.06$0.05$28.00 million$26.94 millionViewN/AView Earnings Details
9/25/2017Q4 17($0.02)$0.07$18.54 million$33.90 millionViewN/AView Earnings Details
5/18/2017Q3 2017$0.10($0.02)$60.00 million$10.82 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.07)($0.06)ViewListenView Earnings Details
11/15/2016Q117($0.08)($0.08)ViewN/AView Earnings Details
9/20/2016Q416($0.08)($0.09)ViewListenView Earnings Details
5/17/2016Q316($0.08)($0.08)ViewN/AView Earnings Details
2/16/2016Q216($0.07)($0.08)ViewN/AView Earnings Details
11/12/2015Q116($0.08)($0.08)ViewListenView Earnings Details
9/21/2015Q415($0.06)($0.09)$2.05 million$12.95 millionViewListenView Earnings Details
5/13/2015Q315($0.04)($0.07)$0.41 millionViewListenView Earnings Details
2/13/2015Q115$0.01$0.03$5.40 million$4.90 millionViewN/AView Earnings Details
11/18/2014Q1 15$0.04$0.01$9.00 million$4.93 millionViewN/AView Earnings Details
9/9/2014Q4 14$0.03($0.04)ViewN/AView Earnings Details
5/13/2014Q3($0.03)($0.01)$500.00 millionViewListenView Earnings Details
2/18/2014Q2 2014($0.04)($0.03)ViewN/AView Earnings Details
11/14/2013Q1($0.05)($0.04)ViewListenView Earnings Details
10/1/2013Q413($0.05)($0.04)ViewListenView Earnings Details
5/14/2013Q3 2013($0.05)($0.04)$0.02 millionViewListenView Earnings Details
2/14/2013Q2 2013$0.01($0.02)ViewN/AView Earnings Details
11/14/2012Q1 2013($0.16)($0.09)ViewN/AView Earnings Details
9/11/2012Q4 2012($0.10)($0.14)ViewN/AView Earnings Details
5/14/2012Q3 2012($0.13)($0.17)ViewN/AView Earnings Details
2/15/2012Q2 2012($0.09)($0.08)ViewN/AView Earnings Details
11/15/2011Q1 2012($0.10)($0.10)ViewN/AView Earnings Details
9/22/2011Q4 2011($0.08)($0.13)ViewN/AView Earnings Details
5/16/2011Q3 2011($0.11)ViewN/AView Earnings Details
2/15/2011Q2 2011($0.09)ViewN/AView Earnings Details
11/15/2010Q1 2011($0.39)ViewN/AView Earnings Details
9/27/2010Q4 2010($3.95)ViewN/AView Earnings Details
5/13/2010Q3 2010($0.20)ViewN/AView Earnings Details
2/16/2010Q2 2010$0.44ViewN/AView Earnings Details
9/8/2009Q4 2009($0.02)ViewN/AView Earnings Details
5/15/2009Q3 2009$0.20$0.01ViewN/AView Earnings Details
2/17/2009Q2 2009$0.20($0.04)ViewN/AView Earnings Details
11/17/2008Q1 2009($0.50)ViewN/AView Earnings Details
9/30/2008Q4 2008($0.60)ViewN/AView Earnings Details
5/13/2008Q3 2008($0.40)($0.60)ViewN/AView Earnings Details
2/8/2008Q2 2008($1.00)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Palatin Technologies (NYSEAMERICAN:PTN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Palatin Technologies (NYSEAMERICAN:PTN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Palatin Technologies (NYSEAMERICAN PTN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Palatin Technologies (NYSEAMERICAN:PTN)
Institutional Ownership by Quarter for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN PTN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2015Joseph Stanley HullDirectorBuy2,500$0.66$1,650.0021,500View SEC Filing  
10/2/2015Robert K Deveer JrDirectorBuy10,000$0.82$8,200.00222,393View SEC Filing  
2/26/2014Bvf Partners L P/IlMajor ShareholderSell540,181$1.14$615,806.34View SEC Filing  
2/19/2014Bvf Partners L P/IlMajor ShareholderSell305,966$1.17$357,980.22View SEC Filing  
3/19/2013Alan W DuntonDirectorBuy1,000$0.58$580.00View SEC Filing  
2/1/2013Alan W DuntonDirectorBuy2,000$0.59$1,180.00View SEC Filing  
1/28/2013Robert I TaberDirectorBuy5,000$0.59$2,950.00View SEC Filing  
12/31/2012Carl SpanaCEOBuy10,000$0.57$5,700.00View SEC Filing  
12/28/2012Stephen T WillsCFOBuy10,000$0.56$5,600.00View SEC Filing  
12/24/2012Perry B MolinoffDirectorBuy10,000$0.61$6,100.00View SEC Filing  
12/14/2012Robert K Deveer JrDirectorBuy21,960$0.70$15,372.00View SEC Filing  
9/4/2012Alan W DuntonDirectorBuy1,000$0.58$580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Palatin Technologies (NYSEAMERICAN PTN) News Headlines

Source:
DateHeadline
A Look at AMAG Pharmaceuticals’ CollaborationsA Look at AMAG Pharmaceuticals’ Collaborations
finance.yahoo.com - February 16 at 4:13 PM
Palatin Technologies (PTN) Posts  Earnings ResultsPalatin Technologies (PTN) Posts Earnings Results
www.americanbankingnews.com - February 13 at 11:12 AM
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
www.prnewswire.com - February 12 at 7:43 AM
Short Interest in Palatin Technologies, Inc. (PTN) Declines By 6.6%Short Interest in Palatin Technologies, Inc. (PTN) Declines By 6.6%
www.americanbankingnews.com - February 9 at 6:36 PM
Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
finance.yahoo.com - February 8 at 5:54 AM
Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational ... - PR Newswire (press release)Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational ... - PR Newswire (press release)
www.prnewswire.com - February 7 at 6:10 AM
Palatin Technologies Announces First Dosing In Phase 1 Study Of PL-8177Palatin Technologies Announces First Dosing In Phase 1 Study Of PL-8177
www.nasdaq.com - February 5 at 3:20 PM
Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 AgonistPalatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist
finance.yahoo.com - February 5 at 3:20 PM
Palatin Technologies, Inc. (PTN) Sees Significant Growth in Short InterestPalatin Technologies, Inc. (PTN) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 24 at 5:40 PM
Palatin Technologies, Inc. (PTN) Sees Significant Increase in Short InterestPalatin Technologies, Inc. (PTN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 10 at 6:04 PM
Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For ... - PR Newswire (press release)Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For ... - PR Newswire (press release)
www.prnewswire.com - January 4 at 10:13 AM
Palatin Technologies, Inc. (PTN) Short Interest UpdatePalatin Technologies, Inc. (PTN) Short Interest Update
www.americanbankingnews.com - December 28 at 2:09 AM
Palatin Technologies, Inc. (PTN) Short Interest Up 53.4% in NovemberPalatin Technologies, Inc. (PTN) Short Interest Up 53.4% in November
www.americanbankingnews.com - December 11 at 8:36 PM
Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs - PR Newswire (press release)Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs - PR Newswire (press release)
www.prnewswire.com - December 11 at 11:00 AM
Short Interest in Palatin Technologies, Inc. (PTN) Rises By 1.0%Short Interest in Palatin Technologies, Inc. (PTN) Rises By 1.0%
www.americanbankingnews.com - November 28 at 1:04 AM

SEC Filings

Palatin Technologies (NYSEAMERICAN:PTN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Palatin Technologies (NYSEAMERICAN:PTN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Palatin Technologies (NYSEAMERICAN PTN) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.